Auxilium announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Xiaflex (collagenase clostridium histolyticum) for the treatment of multiple Dupuytren’s contracture (DC) cords concurrently.

RELATED: Musculoskeletal Disorders Resource Center

The sBLA submission was based on positive results from a global, multicenter Phase 3b trial, in combination with data from earlier MULTICORD ( Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren’s) studies (AUX-CC-861 and AUX-CC-864).

Xiaflex is already approved for the treatment of adult DC patients with a palpable cord and for the treatment of adult men with Peyronie’s disease (PD) with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

For more information call (877) 663-0412 or visit